Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What's Next for NOTES? An Interview with Santiago Horgan, MD

Executive Summary

Medtech Insight interviews Santiago Horgan, MD, professor of surgery at the University of California, San Deigo School of Medicine and a leader in the emerging field of NOTES.

You may also be interested in...



MIS: Challenges in an Evolving Market

Technology and techniques for minimally invasive surgery continue to evolve as medical device manufacturers and clinicians alike look for ways to further minimize the invasiveness, pain, and scarring associated with surgery. At the same time, the economy and health care reform have created challenges for medical device manufacturers. In response to these challenges, mannufacturers competing in the MIS market are developing new products and marketing strategies designed to ease both the economic and environmental impact for providers.

Start-Up News

Noteworthy news from medtech start-ups. This month we profile Arineta, which is developing in-office cardiovascular imaging technology, Ovesco Endoscopy, which is developing a clipping system for NOTES, and Hygieia, which aims to support diabetes patients' glycemic control by providing them with with simple dose-by-dose insulin recommendations.

Start-Up News

Noteworthy news from medtech start-ups. This month we profile Arineta, which is developing in-office cardiovascular imaging technology, Ovesco Endoscopy, which is developing a clipping system for NOTES, and Hygieia, which aims to support diabetes patients' glycemic control by providing them with with simple dose-by-dose insulin recommendations.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel